Anti-CD80 Monoclonal Antibody Uses, Dosage, Side Effects and more
Anti-CD80 Monoclonal Antibody is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Anti-CD80 Monoclonal Antibody is a monoclonal antibody that is being studied in the treatment of follicular non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Anti-CD80 Monoclonal Antibody binds to the protein CD80, which is found on certain normal and cancerous white blood cells.
| Attribute | Details |
|---|---|
| Trade Name | Anti-CD80 Monoclonal Antibody |
| Generic | Galiximab |
| Galiximab Other Names | Anti-CD80 monoclonal antibody, Galiximab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
How Anti-CD80 Monoclonal Antibody works
Anti-CD80 Monoclonal Antibody, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.
Half Life
13 to 24 days
